ASH 2020 | MEDALIST: luspatercept and erythropoiesis biomarkers in MDS
Uwe Platzbecker
• 17 Dec 2020
Uwe Platzbecker, MD, University Hospital Leipzig, Leipzig, Germany, gives an update on the ongoing Phase III MEDALIST trial (NCT02631070) investigating the safety and efficacy of luspatercept in patients with lower-risk myelodysplastic syndrome (MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents. The study found that luspatercept treatment was associated with an increase of erythropoiesis biomarkers. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Uwe Platzbecker, MD, has received honoraria from Jazz, Amgen, Novartis, Geron and AbbVie.
